Autopsy report · NCT03252093

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

“Funding ended”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 4 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Arizona

Sponsor type

University, hospital or other

Conditions

Coronary Artery Bypass Surgery; Cognitive Impairment

Interventions

Angiotensin-(1-7); Placebo for Angiotensin-(1-7)

Participants

6

Sites

5

Countries

United States

Trials that died the same way

• Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
  “Funding ended prematurely” (92% match in meaning)
• Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)
  “funding ending” (91% match in meaning)
• Role of FCI in the Detection of Proctosigmoiditis Caused by IBD
  “Funding period ended” (89% match in meaning)
• A Study of APR-246 in Oesophageal Cancer
  “Funding ceased” (88% match in meaning)
• Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter
  “Funding Stopped” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.